If you have been reading about CJC-1295 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
Homochirality is a uniformity of chirality, or handedness. Objects are chiral when they cannot be superposed on their mirror images. For example, the left and right hands of a human are approximately mirror images of each other but are not their own mirror images, so they are chiral. In chemistry, chirality is a geometric property of some compounds and ions. These compounds exist in two different chiral conformations, enantiomers, often described as the left-handed and right-handed isomers of a compound (denoted by L- (levorotatory to the left) and D- (dextrorotatory to the right), respectively, from how chiral molecules rotate plane-polarized light). The term homochiral is used to describe enantiopure samples of substances in which all the constituents are the same enantiomer. Enantiomers have the same chemical properties in an achiral environment, so abiotic chemical processes typically produce racemic mixtures of chiral compounds, i.e., mixtures containing equal amounts of L- and D-isomers. However, many biologically-synthesized compounds are homochiral. For example, 19 of the 20 genetically-coded proteinogenic amino acids are left-handed, with exception of the achiral glycine, and biological sugars are right-handed. Many theories have been proposed for the "function" of homochirality in nature: it may be a form of information storage and may reduce entropy barriers in the formation of large organized molecules. It has been experimentally verified that amino acids form large aggregates in larger abundance from enantiopure samples than from racemic ones.
[collagen]-(5R)-5-O-[α-D-glucosyl-(1→2)-β-D-galactosyl]-5-hydroxy-L-lysine + H2O = D-glucose + [collagen]-(5R)-5-O-(β-D-galactosyl)-5-hydroxy-L-lysine It belongs to the family of hydrolases, specifically those glycosidases that hydrolyse O- and S-glycosyl compounds. The systematic name is protein-α-D-glucosyl-1,2-β-D-galactosyl-L-hydroxylysine glucohydrolase. Other names in common use include 2-O-α-D-glucopyranosyl-5-O-α-D-galactopyranosylhydroxy-L-lysine glucohydrolase, and lysine glucohydrolase.
However, Smithwick et al.'s study noted that, after further preparation, this irregular surface was simply a layer of sediment with a different color than the rest of the slab. The 'frill' or 'halo' of collagen identified by Feduccia was also determined to be misidentified sediment surrounding one of the specimens. Smithwick et al.'s study concluded by stating that the integument preserved on Sinosauropteryx closely resembled that of birds preserved in the same formation. Purported features of collagen fibers were in fact misidentified shadows formed by scratches or irregular sediment, a misidentification perpetuated by the low quality of early Sinosauropteryx photographs.
== Further reading == Wolf, Jeanne; Ali Larter, Always the Bad Girl; Parade; August 24, 2009; Retrieved July 24, 2010 Cavaco, Paul; Ali Larter: Her Allure Photo Shoot; Allure; Retrieved July 24, 2010 Our Heroine; Cosmopolitan; Retrieved July 24, 2010 Hiltbrand, David; Split personalities make solid role for Ali Larter; Chicago Tribune; January 31, 2007; Retrieved July 24, 2010 Longsdorf, Amy; 'Obsessed' star Ali Larter calls Allentown area a 'safe haven'; The Morning Call; April 26, 2009; Retrieved July 26, 2010 Passafuime, Rocco; Still Our Hottest Hero; The Cinema Source; September 18, 2010; Retrieved September 25, 2010
Sources: en.wikipedia.org
=== Rehabilitation === Professor Cathy Schnieder of International Service at American University noted that in 1989, blacks, representing 12-15% of all drug use in the United States, made up 41% of all arrests. That was a noted increase from 38% in 1988. Whites were 47% of those in state-funded treatment centers but fewer than 10% of those committed to prison.
=== Ministry of Finance === Horacio Cartes picked Peña to replace Germán Rojas as finance minister in 2015, following Rojas's resignation on personal grounds. As Peña took office, Cartes described him as a "bright young man" who would reinvigorate Paraguay's economy in the face of low global soy prices and a slow regional export market. As Minister of Finance in 2016 and 2017, Peña promoted the project to create the Superintendency of Retirements and Pensions. Peña indicated, “There have already been situations of embezzlement with the case of the Pension Fund of the Binational Itaipú (Cajubi).” The Itaipu Retirement and Pension Fund (Cajubi) and the Itaipu Workers' Union (STEIBI) opposed the project. In a joint press conference in November 2016, the two groups stated that they saw the plan as an “unconstitutional” violation, further describing the proposed legislation as “an imminent danger from a greedy person, who is looking for ways to extract money from people and who is the Minister of Finance.” On May 17, 2018, Cajubi's director and legal advisor, Adelio Dolores Aquino, presented Cajubi's position against the creation of a Superintendency on the TV Unicanal's program Sin Vueltas. As President, Peña continued to advocate for the creation of the Superintendency of Retirement and Pensions, arguing that it was necessary to prevent problems like the Cajubi case.
Human mitochondrial DNA encodes 13 proteins of the respiratory chain, while most of the estimated 1,500 proteins and components targeted to mitochondria are nuclear-encoded. Defects in nuclear-encoded mitochondrial genes are associated with hundreds of clinical disease phenotypes including anemia, dementia, hypertension, lymphoma, retinopathy, seizures, and neurodevelopmental disorders. A study by Yale University researchers (published in the February 12, 2004, issue of the New England Journal of Medicine) explored the role of mitochondria in insulin resistance among the offspring of patients with type 2 diabetes. Other studies have shown that the mechanism may involve the interruption of the mitochondrial signaling process in body cells (intramyocellular lipids). A study conducted at the Pennington Biomedical Research Center in Baton Rouge, Louisiana showed that this, in turn, partially disables the genes that produce mitochondria.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.